Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis

Vedolizumab (VDZ) is an α4β7 integrin-antibody used to manage refractory ulcerative colitis (UC). This retrospective multicenter study aimed to identify predictors of efficacy or the time points when evaluation of VDZ therapy for UC would be most useful. We compiled data on 87 patients with moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Haga, Keiichi, Shibuya, Tomoyoshi, Osada, Taro, Sato, Shunsuke, Fukuo, Yuka, Kobayashi, Osamu, Yamada, Toshio, Asaoka, Daisuke, Ito, Kentaro, Nomura, Kei, Haraikawa, Mayuko, Nomura, Osamu, Fukushima, Hirofumi, Murakami, Takashi, Ishikawa, Dai, Hojo, Mariko, Nagahara, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599457/
https://www.ncbi.nlm.nih.gov/pubmed/36289788
http://dx.doi.org/10.3390/biomedicines10102526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599457/
https://www.ncbi.nlm.nih.gov/pubmed/36289788
http://dx.doi.org/10.3390/biomedicines10102526

Ejemplares similares